72548-79-9

Usage

Uses

Used in Chemical Applications:
3-Pyrrolidin-1-yl-benzoic acid is used as a chemical intermediate for the synthesis of various compounds. Its unique structure allows it to be a versatile building block in the development of new molecules with potential applications in different industries.
Used in Pharmaceutical Applications:
3-Pyrrolidin-1-yl-benzoic acid is used as a potential drug candidate for the development of new therapeutic agents. Its pyrrolidine and benzoic acid groups may contribute to its biological activity, making it a promising compound for further research and development in the pharmaceutical field.
Used in Research and Development:
3-Pyrrolidin-1-yl-benzoic acid is used as a research compound for studying its chemical properties, reactivity, and potential interactions with other molecules. This information can be valuable for understanding its potential applications and for designing new compounds with desired properties.

InChI:InChI=1/C11H13NO2/c13-11(14)9-4-3-5-10(8-9)12-6-1-2-7-12/h3-5,8H,1-2,6-7H2,(H,13,14)

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 4518-10-9 Methyl 3-aminobenzoate 
• 186086-71-5 N-(3-carbomethoxyphenyl)pyrrolidine 

Downstream Products

• 1092504-43-2 C₃₅H₄₁Cl₂N₇O₃ 
• 1092504-44-3 C₃₅H₄₄Cl₂N₆O₂ 
• 1092504-70-5 C₂₁H₂₆N₄O 
• 1394161-90-0 5-(3-(pyrrolidin-1-yl)phenyl)oxazole-4-carboxylic acid 
• 1394161-89-7 methyl 5-(3-(pyrrolidin-1-yl)phenyl)oxazole-4-carboxylate 
• 1383341-12-5 3-(1-pyrrolidinyl)-N-[1-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]benzamide 
• 1092504-46-5 C₂₈H₂₈Cl₂N₄O₃ 
• 1092504-69-2 C₂₆H₃₄N₄O₃ 
• 168162-35-4 1-(3-Isocyanato-phenyl)-pyrrolidine 

Relevant academic research and scientific papers

BEZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES

The invention concerns the use of amide derivatives of formula (I) wherein: R1 and R2 are substituents such as hydroxy, C1-6alkoxy, mercapto, C1-6alkylthio, amino, C1-6alkylamino and di-(C1-6alkyl)amino; m and p are independently 0-3; R3 is C1-4alkyl; q is 0-4; and R4 is aryl or cycloalkyl; or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of diseases or medical conditions mediated by cytokines

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist

A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analogue L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biological activity. The compounds were screened for their ability to inhibit the binding of [125I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [3H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compounds to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in viva included determination of ED50 values in the rat acid secretion model for selected compounds and an examination of the effect of these compounds on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and intravenous administration. Two compounds, i.e. (3R)-N- [1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N- [1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21 nmol/kg po in dogs. 15e is currently under clinical investigation for the treatment of gastro-oesophagal reflux disease (GORD).